Cancer Research UK, Cytovation and the Norwegian Cancer Society announce a multi-national phase II clinical trial (CLARITY; ISRCTN15479264) for people with advanced adrenocortical carcinoma, a rare and aggressive cancer affecting the adrenal glands. The trial currently has multiple sites open in the UK with further sites planned across the UK and Europe.
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.
